Topics:

Colorectal Cancer

Full-Spectrum Colonoscopy Decreased Adenoma Miss Rate

The use of full-spectrum colonoscopy significantly decreased the number of adenomas missed during an examination compared with the use of forward-viewing colonoscopy, according to the results of an international, multicenter study.

Colorectal Cancer

Adding cetuximab to FOLFIRI resulted in improvements in survival and objective response in patients with KRAS codon exon 2 wild-type metastatic colorectal cancer.

The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.

The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.

Rectal cancer patients who completed neoadjuvant therapy with a clinical complete response had similar 4-year survival rates as patients who opted for surgery.

Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.

The results of a recent meta-analysis suggest that carriers of the MLH1 or MSH2 mutations associated with Lynch syndrome could delay regular colonoscopies until age 30.

Pages

Subscribe to Colorectal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.